C. Ola Landgren, MD, PhD
The treatment paradigm of multiple myeloma has been flooded with new agents and combinations, as well as the potential for chimeric antigen receptor (CAR) T-cell therapy, explains C. Ola Landgren, MD, PhD.
State of the Science Summit™ on Hematologic Malignancies. In an interview during the meeting, Landgren shared his insight on CAR T-cell therapy, sequencing, and triplet and quadruplet regimens in myeloma.
OncLive: Can you please discuss your presentation?
: I gave a presentation on the treatment landscape for patients with relapsed/refractory multiple myeloma. As illustrated in my lecture, there are many options in terms of treatment. I spoke about the fact that relapse varies greatly from patient to patient. It can be a biochemical or a symptomatic relapse. Depending on how relapse presents, there are different options to consider.
... to read the full story